Abstract: The present disclosure provides methods for treating multiple myeloma that comprise administering isatuximab to the individual at a dose of 10 mg/kg on Days 1, 8, 15, and 22 of a first 28-day cycle; administering the isatuximab at a dose of 10 mg/kg on Days 1 and 15 of a 28-day cycle, e.g., for at least 11 cycles, or e.g., until the individual achieves or is determined to achieve at least Very Good Partial Response (VGPR) to treatment; and administering the isatuximab at a dose of 10 mg/kg once every 28 days of one or more additional 28-day cycles.

Abstract: The present disclosure relates to combination cancer therapies targeting CD38 and TGF-? using antibodies specific for these targets. Also provided are compositions useful in the therapies.

Abstract: The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.

Abstract: A method is provided for treating cancer in a patient comprising administering to said patient a proteasome inhibitor at least three days a week.

Abstract: The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.

Abstract: A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-743